Endocyte Announces Second Quarter 2018 Financial Results and Operational Update Call
July 25 2018 - 8:01AM
Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company
developing targeted therapeutics for personalized cancer treatment,
today announced that the company will host a conference call on
Tuesday, July 31st, at 8:30 a.m. EDT to discuss its second quarter
financial results and provide an operational update.
Investors and the general public are invited to listen to a live
webcast of the call, which can be accessed in the Investors &
News section of the Company’s website at www.endocyte.com or by
dialing (877) 845-0711 (U.S./Canada) or (760) 298-5081
(International).
The webcast will be recorded and available on the Company’s
website for 90 days following the call.
Website Information
Endocyte routinely posts important information
for investors on its website, www.endocyte.com, in the “Investors
& News” section. Endocyte uses this website as a means of
disclosing material information in compliance with its disclosure
obligations under Regulation FD. Accordingly, investors should
monitor the “Investors & News” section of Endocyte’s website,
in addition to following its press releases, SEC filings, public
conference calls, presentations and webcasts. The information
contained on, or that may be accessed through, Endocyte’s website
is not incorporated by reference into, and is not a part of, this
document.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing
targeted therapies for the personalized treatment of cancer. The
company's drug conjugation technology targets therapeutics and
companion imaging agents specifically to the site of diseased
cells. Endocyte's lead program is a prostate specific membrane
antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617,
entering phase 3 for metastatic castration-resistant prostate
cancer (mCRPC). Endocyte also expects to have an Investigational
New Drug application submitted in the fourth quarter of 2018 for
its adaptor-controlled CAR T-cell therapy which will be initially
studied in osteosarcoma. For additional information, please visit
Endocyte's website at www.endocyte.com.
Investor Contact:Michael Schaffzin, Stern
Investor Relations, Inc., (212) 362-1200, michael@sternir.com
Endocyte, Inc. (delisted) (NASDAQ:ECYT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Endocyte, Inc. (delisted) (NASDAQ:ECYT)
Historical Stock Chart
From Apr 2023 to Apr 2024